Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids

Executive Summary

Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to epidemic.

You may also be interested in...



Unintended Consequences Of Broad Opioid-Sparing Claims Worries US Panel

FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices. 

US FDA Chief Gottlieb Envisions Tiered Mandates For Opioid Training System

Mandatory training could be reserved for physicians who want to prescribe opioids for longer-term use, as opposed to those who would prescribe recommended amounts in blister packs; evidence that blister packs would affect prescribing still is needed, however.

Medicare Opioid Abuse Prevention Measures To Be Enhanced In 2019

Part D plans would need expanded point-of-sale 'edits' for high-dose prescriptions and supply limits for patients new to opioids under proposal in 2019 'call letter' for the Medicare pharmacy benefit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel